ReceptoPharm  
Home   Drug Development   CRO Services   Newsroom   About ReceptoPharm   Contact
» Recent News
» Archives
» E-Alerts
 
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
 
CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More

Newsroom

Nutra Pharma Announces Amarey Nova Medical as its Exclusive Nyloxin Distributor in Colombia
August 09, 2010

Nutra Pharma has selected Amarey Nova Medical S.A. to serve as the exclusive distributor in Colombia for its Nyloxin-branded pain relievers.

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has selected Amarey Nova Medical S.A. to serve as the exclusive distributor in Colombia for its Nyloxin-branded pain relievers.

“We are excited to be working with Amarey Nova Medical to introduce Nyloxin throughout the Colombian healthcare market,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As one of the leading pharmaceutical distributors in Colombia, Amarey brings the expertise and ability to support the growth of new healthcare products such as Nyloxin throughout Colombia,” he added.

Amarey Nova Medical S.A., which offers over 23 years of experience in the Colombian pharmaceutical market, provides 100% sales coverage throughout Colombia. The Company’s sales force is located in Bogota, Cali, Medellin, Barranquilla, Bucaramanga, Cucuta, and Pereira.  Companies, whose products are represented by Amarey, include Eli Lilly, Pfizer, Stryker, Merck Novo Nordisk, and Roche.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Announcing Amarey Nova Medical as the Company’s exclusive Nyloxin distributor in Colombia should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Recent News
November 05, 2010
Nutra Pharma Awarded Grant under the Qualifying Therapeutic Discovery Project Program
 
E-Alerts
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name:
Email:
NPC